A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
- Conditions
- Cancer pain
- Registration Number
- JPRN-UMIN000040584
- Lead Sponsor
- Tohoku University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Not provided
Patients whose physicians consider it inappropriate to participate in the research. Patients who are pregnant, lactating, or may be pregnant. Patients with diabetes who have poor glycemic control who need additional insulin injections Patients with an infection-caused fever of 38 degrees or higher Patients undergoing treatment for an active gastrointestinal ulcer Patients with diagnoses of hematological malignancy Serious adverse events due to corticosteroid in the past Patients who started a new anticancer treatment with a molecularly targeted agency or immune checkpoint inhibitor within 2 weeks, or are scheduled to start the treatment within 1 week Patients were administrated corticosteroids more than the scheduled dose on the day before the start of treatment Patients scheduled to administrate corticosteroids more than its regular doses in one week for the treatment of adverse effects by anticancer therapy Patients who are scheduled to receive surgery for the pain control in a week
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the difference of pain intensity (worst pain in 24 hours) between baseline, 72 hours later and 168 hours later.
- Secondary Outcome Measures
Name Time Method